114 results
The aim of the study is to investigate the effect of magnetic resonance (MR) based online adaptive radiotherapy (RT) for treatment of low to intermediate risk localized prostate carcinoma (PCa) on the radiotherapy dose on the prostate and organs at…
To analyse the safety of oestradiol in the setting of endocrine treatment for locally extended prostate cancer adjuvant to radiotherapy.
The primary objective of this study is to assess the potential of quantitative MRI parameters to predict nodal disease stage of prostate cancer by correlating quantitative MRI measurements of the local prostate to the presence of metastases as seen…
Determine whether the finger prick blood collection procedure can reliably replace venepuncture blood collection for the following tests: PSA, Covid-19 serology, HbA1c and a series of standard and routine chemistry tests.
The primary objective of this study is to determine histological ablative efficacy by absence of vital (tumour) cells in the treated prostate zone with (multi)fibre setup in men with PCa scheduled for radical prostatectomy. The secondary objectives…
To assess toxicity of MRI guided focal salvage high-dose-rate brachytherapy as monotherapy in patients with locally recurrent prostate cancer. As secondary objectives, technical feasibility, quality of life and biochemical free survival (Phoenix…
This study has been transitioned to CTIS with ID 2024-513186-39-00 check the CTIS register for the current data. Primary objective:To evaluate the efficacy of nivolumab in combination with ipilimumab in molecular pre-selected patients with…
The current research is focused on finding a method that is able to better stratify the patients. A possible method could be to study PSA in more detail, specifically the modifications which are present on the protein. One of these modifications is…
The primary objective is efficacy of atezolizumab in advanced penile cancer patients measured by progression-free survival.
This study has been transitioned to CTIS with ID 2023-506987-15-00 check the CTIS register for the current data. 1) Objective: To evaluate the safety and tolerability of the pembrolizumab combination therapy.2) Objective: To estimate PSA response…
There are two co-primary study objectives:• Region-level positive predictive value (PPV) defined as the percentage of all PET-positive regions containing at least one true positive lesion (exactly localized correspondence between [18F]PSMA-1007 PET…
This study has been transitioned to CTIS with ID 2024-514168-15-00 check the CTIS register for the current data. Primary: To determine the maximum tolerated dose (MTD) of 1 or 2 cycli Lu-PSMA when given concurrent with EBRT+ADT. Secondary: To…
This study has been transitioned to CTIS with ID 2023-508150-26-00 check the CTIS register for the current data. Primary Objectives:- To determine the BE of a RS FDC tablet formulation of niraparib and Abiraterone Acetate with respect to niraparib…
This study has been transitioned to CTIS with ID 2024-513729-22-01 check the CTIS register for the current data. 1.1 Primary study objectives To investigate the safety, tolerability and biochemical effects of 225Ac-PSMA injected in patients with…
Primary: * To assess Clinical Benefit Rate (CBR) in patients with mCRPC and poor prognostic factors treated with cabazitaxel or novel hormonal agents (abiraterone OR enzalutamide) as second-line therapy.Secondary: * To formally compare CBR in both…
To investigate the frequency of V*9Vδ2-T cells in patients with metastatic castration-resistant prostate cancer
The primary objective is to collect high-quality 3D mpUS and histology data, to train and improve the classifier algorithm with the goal of achieving an accurate ultrasound imaging tool for the detection of clinically significant prostate cancer.…
This study has been transitioned to CTIS with ID 2024-515821-27-00 check the CTIS register for the current data. Primary objectivesPart 1 Dose Escalation for LAVA-1207 alone, LAVA-1207 plus LDSC IL-2, and LAVA-1207 plus pembrolizumab• To investigate…
To investigate the technical feasibility of inserting a brachytherapy needle into the prostate to a defined tumour target point using a robotic device.
To estimate the objective response rate (ORR) by RECIST 1.1 in subjects with measurable disease assessed by central imaging vendor in Cohorts 1 and 2 combined, Cohort 1, Cohort 2 and Cohort 4.